Ultragenyx Pharmaceutical reported $-1.16 in EPS Earnings Per Share for its fiscal quarter ending in September of 2026.


Fiscal Calendar Actual Consensus Previous Date
FY2026Q3 Sep/2026 -1.16 -1.04 -1.81 Nov/03
FY2026Q2 Jun/2026 -0.90 -1.23 -1.17 Aug/04
FY2026Q1 Mar/2026 -1.84 -1.43 -1.57 May/05
FY2025Q4 Dec/2025 -1.29 -1.17 -1.39 Feb/12
FY2025Q3 Sep/2025 -1.81 -1.23 -1.40 Nov/04




Eps Change Date
Acadia Pharmaceuticals USD 0.31 0.13 Sep/2026
Agios Pharmaceuticals USD -1.09 0.6 Sep/2026
Alnylam Pharmaceuticals USD 16.26 14.42 Sep/2026
BioCryst Pharmaceuticals USD 0.3 0.87 Jun/2026
BioMarin Pharmaceutical USD 0.23 0.97 Sep/2026
Immunic USD -0.1 0.03 Dec/2025
Insmed USD -0.46 0.4 Sep/2026
Ionis Pharmaceuticals USD 0.66 1.35 Sep/2026
Karyopharm Therapeutics USD -1.02 1.2 Mar/2026
Kyowa Hakko Kirin JPY 40.22 4.73 Sep/2026
MacroGenics USD 0.31 0.89 Jun/2026
Moderna USD 0.38 2.35 Sep/2026
Neurocrine Biosciences USD 3.29 0.44 Sep/2026
PTC Therapeutics USD -0.62 1.54 Sep/2026
Puma Biotechnology USD 0.41 0.5 Sep/2024
Regeneron Pharmaceuticals USD 20.07 5.78 Sep/2026
Sarepta Therapeutics USD 0.13 0.51 Sep/2026
Ultragenyx Pharmaceutical USD -1.16 0.26 Sep/2026
Vertex Pharmaceuticals USD 4.76 0.03 Sep/2026